Femasys (NASDAQ:FEMY) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Femasys (NASDAQ:FEMY) from a hold rating to a sell rating in a report published on Saturday.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Femasys in a research note on Thursday, January 22nd. Lake Street Capital began coverage on shares of Femasys in a research note on Tuesday, March 3rd. They issued a “buy” rating and a $1.50 price objective for the company. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Femasys Stock Down 3.2%

Shares of NASDAQ:FEMY opened at $0.48 on Friday. The company has a market capitalization of $28.21 million, a PE ratio of -0.67 and a beta of -2.53. The company has a current ratio of 1.16, a quick ratio of 0.61 and a debt-to-equity ratio of 0.01. Femasys has a twelve month low of $0.31 and a twelve month high of $1.39. The firm has a 50 day simple moving average of $0.55 and a 200-day simple moving average of $0.63.

Institutional Trading of Femasys

Several institutional investors and hedge funds have recently added to or reduced their stakes in FEMY. Kovack Advisors Inc. purchased a new position in shares of Femasys in the 4th quarter valued at approximately $27,000. HRT Financial LP acquired a new position in shares of Femasys in the fourth quarter valued at approximately $30,000. Cetera Investment Advisers purchased a new stake in shares of Femasys during the fourth quarter worth approximately $36,000. Osaic Holdings Inc. purchased a new stake in shares of Femasys during the second quarter worth approximately $45,000. Finally, State Street Corp lifted its holdings in shares of Femasys by 43.5% during the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after purchasing an additional 24,500 shares during the period. 65.27% of the stock is owned by hedge funds and other institutional investors.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.